VistaPath, a Cambridge, Mass.-based provider of artificial intelligence (AI)-based, data-driven pathology processing platforms, secured $4 million in seed funding.
The round was led by Moxxie Ventures with participation from NextGen Venture Partners and First Star Ventures.
The company intends to use the funds to expand operations and its development efforts.
Led by Timothy Spong, CEO, VistaPath provides Sentinel, a pathology processing platform designed to deliver a range of solutions for critical lab processes. The company’s first application, released in 2021, is a tissue grossing platform that automates the process of receiving, assessing, and processing tissue samples.
Additional applications are slated to be released later this year.
FinSMEs
30/06/2022